3-tributylstannyl-2-formyl-6-methoxypyridine | 239463-13-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-tributylstannyl-2-formyl-6-methoxypyridine
• 英文别名: (2-formyl-6-methoxy3-pyridyl)tributylstannane；6-Methoxy-3-tributylstannylpyridine-2-carbaldehyde
• CAS: 239463-13-9
• 化学式: C₁₉H₃₃NO₂Sn
• 分子量: 426.187
• InChiKey: NXSGMAIBPJOSHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.96
• 重原子数：
  23
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-tributylstannyl-2-formyl-6-methoxypyridine 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium chlorite 、 sodium dihydrogenphosphate dihydrate 、 2-甲基-2-丁烯 、 copper(II) oxide 作用下， 以 水 、 N,N-二甲基甲酰胺 、 乙腈 、 叔丁醇 为溶剂， 生成 3-[4-(1(S)-t-butyldimethylsilyloxymethyl-2,2-dimethylpropylcarbamoyl)-2-benzyloxycarbonylphenyl]-6-methoxy-2-pyridinecarboxylic acid
  参考文献：
  名称：

  Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold

  摘要：

  In this Letter, we describe the synthesis of several nonamidine analogs of biaryl acid factor VIla inhibitor 1 containing weakly basic or nonbasic P1 groups. 2-Aminoisoquinoline was found to be an excellent surrogate for the benzamidine group (compound 2) wherein potent inhibition of factor VIla is maintained relative to most other related serine proteases. In an unanticipated result, the m-benzamide P1 (compounds 21a and 21b) proved to be a viable benzamidine replacement, albeit with a 20-40 fold loss in potency against factor Vlla. (C) 2013 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.06.028
• 作为产物：
  描述：

  6-甲氧基吡啶-2-甲醛 、 三丁基氯化锡 在 正丁基锂 、 N,N,N'-三甲基乙二胺 作用下， 以 四氢呋喃 、 正己烷 、 环己烷 为溶剂， 以53%的产率得到3-tributylstannyl-2-formyl-6-methoxypyridine
  参考文献：
  名称：

  Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold

  摘要：

  In this Letter, we describe the synthesis of several nonamidine analogs of biaryl acid factor VIla inhibitor 1 containing weakly basic or nonbasic P1 groups. 2-Aminoisoquinoline was found to be an excellent surrogate for the benzamidine group (compound 2) wherein potent inhibition of factor VIla is maintained relative to most other related serine proteases. In an unanticipated result, the m-benzamide P1 (compounds 21a and 21b) proved to be a viable benzamidine replacement, albeit with a 20-40 fold loss in potency against factor Vlla. (C) 2013 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.06.028

文献信息

• Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors
  申请人：——

  公开号：US20040220206A1

  公开（公告）日：2004-11-04

  The present invention provides compounds of Formula (I): 1 or a stereoisomer or pharmaceutically acceptable salt or hydrate form thereof, wherein the variables A, B, L 1 , L 2 , X 1 , X 2 , X 3 , X 4 and W are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了Formula (I)的化合物：1或其立体异构体或药用可接受的盐或水合物形式，其中变量A、B、L1、L2、X1、X2、X3、X4和W如本文所定义。Formula (I)的化合物可作为凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂，例如凝血酶、因子Xa、因子XIa、因子IXa、因子VIIa和/或血浆激肽。具体地，涉及具有选择性因子XIa抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用这些药物组合物治疗血栓栓塞性和/或炎症性疾病的方法。
• Amidino derivatives and drugs containing the same as the active ingredient
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US06358960B1

  公开（公告）日：2002-03-19

  The novel amidino derivatives of the formula (I): wherein all the symbols are as in specification defined; have an inhibitory activity of a blood coagulation factor VIIa and are useful for treatment and/or prevention of several angiopathy caused by enhancing a coagulation activity, such as disseminated intravascular coagulation, coronary thrombosis, cerebral infarction, cerebral embolism, transient ischemic attack, cerebrovascular disorders, pulmonary vascular diseases, deep venous thrombosis, peripheral arterial obstruction, thrombosis after artificial vascular transplantation and artificial valve transplantation, post-operative thrombosis, reobstruction and restenosis after coronary artery bypass operation, reobstruction and restenosis after PTCA or PTCR, thrombosis by extracorporeal circulation and procoagulative diseases such as glomerlonephriitis.

  该式(I)的胍基衍生物小说：其中所有符号均如规范中所定义；具有抑制血凝血因子VIIa的活性，并可用于治疗和/或预防由增强凝血活性引起的多种血管病，如弥散性血管内凝血、冠状动脉血栓形成、脑梗死、脑栓塞、短暂性缺血发作、脑血管疾病、肺血管疾病、深静脉血栓形成、周围动脉阻塞、人工血管移植后血栓形成和人工瓣膜移植后血栓形成、术后血栓形成、冠状动脉旁路手术后再阻塞和再狭窄、PTCA或PTCR后再阻塞和再狭窄、体外循环引起的血栓形成以及像肾小球肾炎这样的促凝病。
• Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold
  作者：Scott A. Bolton、James C. Sutton、Rushith Anumula、Gregory S. Bisacchi、Bruce Jacobson、William A. Slusarchyk、Uwe D. Treuner、Shung C. Wu、Guohua Zhao、Zulan Pi、Steven Sheriff、Rebecca A. Smirk、Sharon Bisaha、Daniel L. Cheney、Anzhi Wei、William A. Schumacher、Karen S. Hartl、Eddie Liu、Robert Zahler、Steven M. Seiler

  DOI：10.1016/j.bmcl.2013.06.028

  日期：2013.9

  In this Letter, we describe the synthesis of several nonamidine analogs of biaryl acid factor VIla inhibitor 1 containing weakly basic or nonbasic P1 groups. 2-Aminoisoquinoline was found to be an excellent surrogate for the benzamidine group (compound 2) wherein potent inhibition of factor VIla is maintained relative to most other related serine proteases. In an unanticipated result, the m-benzamide P1 (compounds 21a and 21b) proved to be a viable benzamidine replacement, albeit with a 20-40 fold loss in potency against factor Vlla. (C) 2013 Published by Elsevier Ltd.